Targeting Costimulatory Molecules to Improve Antitumor Immunity

Daria Capece, Daniela Verzella, Mariafausta Fischietti, Francesca Zazzeroni, and Edoardo Alesse

Department of Experimental Medicine, University of L’Aquila, Via Vetoio 10, Cappito II, 67100 L’Aquila, Italy

Correspondence should be addressed to Edoardo Alesse, edoardo.alesse@univaq.it

Received 1 August 2011; Revised 12 October 2011; Accepted 16 November 2011

Academic Editor: Dass S. Vinay

Copyright © 2012 Daria Capece et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The full activation of T cells necessitates the concomitant activation of two signals, the engagement of T-cell receptor by peptide/major histocompatibility complex II and an additional signal delivered by costimulatory molecules. The best characterized costimulatory molecules belong to B7/CD28 and TNF/TNFR families and play crucial roles in the modulation of immune response and improvement of antitumor immunity. Unfortunately, tumors often generate an immunosuppressive microenvironment, where T-cell response is attenuated by the lack of costimulatory molecules on the surface of cancer cells. Thus, targeting costimulatory pathways represent an attractive therapeutic strategy to enhance the antitumor immunity in several human cancers. Here, latest therapeutic approaches targeting costimulatory molecules will be described.

1. Introduction

T-cell activation requires a double signal, as stated in the “two signal theory.” The first signal is provided by the engagement of the T-cell receptor (TCR) by its cognate antigen, through the interaction with the peptide-major-histocompatibility complex (MHC) on antigen presenting cells (APCs). In 1987, Jenkins et al. [1] demonstrated that TCR engagement was not sufficient for a full T-cell activation. Costimulatory molecules expressed on the surface of APCs are responsible for the second signal, known as costimulatory signal. The interactions of costimulatory molecules with cognate receptors on the surface of T cells result in clonal T-cell expansion and differentiation, as well as in carrying out their effector functions [2]. For several costimulatory molecules a bidirectional signaling has been reported, because their signaling pathways are also directed toward APCs. The lack of costimulation results in a nonresponsive state of T cells, known as anergy [3]. Following the initial activation, coinhibitory molecules are induced to dampen the immune response. Complex interactions implicating both overlapping and distinct costimulatory pathways underlie the generation of the immune response; thus, the tightly regulated expression of costimulatory and coinhibitory molecules, both in time and space, is crucial to provide an efficient immune protection avoiding autoimmunity.

Costimulatory molecules belong to two major families: B7/CD28 family and tumor necrosis factor (TNF)/tumor necrosis factor receptor (TNFR) family. All molecules belonging to B7/CD28 family are members of the larger immunoglobulin superfamily and are involved in the triggering of cell-mediate immune response. Instead, the TNF/TNFR family members are involved in the later phases of T-cell activation and are induced from hours to days following the TCR engagement [2].

The presence of an efficient costimulation is crucial for improving antitumor immunity. In fact, one of the mechanisms through which tumors are able to evade immune surveillance is the lower expression of costimulatory molecules or the upregulation of coinhibitory molecules. The lack of costimulation in the tumor microenvironment could be responsible for the generation of anergic T cells and, consequently, the absence of an appropriate antitumor immune response [4].

This paper focuses on the major costimulatory pathways belonging to B7/CD28 and TNF/TNFR families, underlying
the potential of targeting these pathways in cancer immuno-
therapy.

2. The B7:CD28 Family

2.1. B7-1/B7-2:CD28/CTLA-4. The B7-1/B7-2:CD28/CTLA-
4 pathway is the best characterized pathway of T-cell
costimulation and coinhibition and symbolizes the classical
way where the ligand can bind two receptors for regulating
both T-cell activation and tolerance. The balance between
the activating and inhibitory signals derived from the
engagement of CD28 and CTLA-4, respectively, is crucial to
assure protective immunity, without falling into undesired
autoimmunity.

B7-1 (CD80) and B7-2 (CD86) are two ligands for both
CD28 and CTLA-4. The expression of B7-1 and B7-2 is
restricted to professional APCs, such as dendritic cells (DCs),
macrophages, and B cells. CD28 is constitutively expressed
on the surface of T cells, whereas CTLA-4 expression is
induced 24–48 hours after T-cell activation, due to the action
of lymphocyte cell kinase (Lck), Fyn and resting lymphocyte
kinase (RLK) that phosphorylates CTLA-4, thus increasing
its transport to the cell surface and preventing its internal-
ization. CTLA-4 was shown to have higher affinity for both
B7-1 and B7-2 than CD28 receptor [4, 5].

The B7-1/B7-2:CD28 pathway is the strongest costimula-

tory signal delivered by APCs to provide a full activation
of T cells, promoting their proliferation and IL-2 secretion
[4]. The intracellular signaling of B7-1/B7-2:CD28 pathway
occurs through the activation of phosphatidylinositol-3-
kinase (PI3K)/Akt/Nuclear Factor-kappa B (NF-κB) and the
mitogen-activated protein kinases (MAPKs) pathway, which
support cell survival, memory development, proliferation,
and cytokines production [6].

In contrast to the costimulatory signal derived from the
binding of CD28 to B7-1 and B7-2, the engagement of
CTLA-4 by these ligands provides a negative regulation
of the immune response, as proved by the characterization
of CTLA-4 deficient mice (CTLA-4–/–). In fact, CTLA-
4–/– mice showed lymphoproliferative disorders that led
to neonatal death after 3–4 weeks of age, underscoring the
central role of this receptor in induction of peripheral
tolerance through a direct inhibition of CD28 signaling or
by regulating the availability of cofactors necessary for TCR
signaling [5]. Because of the lack of intrinsic enzymatic
activity, CTLA-4 binds signaling molecules, such as protein
phosphatase 2A (PPA-2) and Src homology phosphatase 2
(SHP-2), which mediate its effects [5]. CTLA-4 should be
also involved in the regulation of CD4+CD25+ T regulatory
cells (Tregs), which constitutively expressed this receptor
on their surface [5]. Although still debated, part of the
inhibitory function of CTLA-4 may result from its ability
to enhance the generation of Tregs or, as an alternative, to
modulate their functions. This hypothesis is supported by
the evidence that mice with a Tregs-conditional deletion
developed lymphoproliferative syndrome [7]. In addition,
CTLA-4 blockade caused the abrogation of Treg functions in
vivo [8].

The tumor microenvironment is often characterized by
the presence of anergic T cells, due to the lack of positive
costimulatory molecules, mainly B7-1 and B7-2, on the
surface of cancer cells [9]. One strategy to revert this scenario
is to force B7 expression on tumor cells, rendering them able
to activate T-cell immune response.

Several studies showed that the induction of B7-1 on
tumor cells was sufficient to stimulate the CD8+ T cell-
mediated rejection in several tumor models, as well as a
memory response, but was insufficient to mediate rejection
of poorly immunogenic tumors [4]. Several phase I clinical
trials evaluated the efficacy of B7-1 transfected tumor cell
vaccines, with or without IL-2, with encouraging preliminary
results in patients affected by metastatic renal carcinoma
and nonsmall cell lung cancer (Table 1) [10, 11]. In a phase
II trial, 39 patients with metastatic renal carcinoma were
vaccinated with B7-1-transfected autologous tumor cells in
combination with systemic IL-2 [12]. The authors observed
3% pathologic complete response, 5% partial response,
64% stable disease, 28% disease progression, and a median
survival of 21.8 months; similar results have been reported
for IL-2 alone [12].

B7-1 was also included in vaccine along with specific
antigens, such as carcinoembryonic antigen (CEA) (Table 1).
Recently, in a phase II trial for metastatic colorectal cancer,
Kauffman et al. used a nonreplicating canaripox virus vector
(ALVAC) expressing CEA and B7-1 in combination with
chemotherapy. The observed objective response rate of
40.4% was similar to that reported for chemotherapy alone
[13]. Improvements on new vaccine strategies led to the
generation of viral vectors expressing a triad of costimulatory
molecules (TRICOMs), such as B7-1, intercellular adhesion
molecule 1 (ICAM-1), and lymphocyte function-associated
antigen 3 (LFA-3), along with CEA, mucin-cell-surface-
associated 1 (MUC-1), and prostate-specific antigen (PSA)
antigens, with promising results in preclinical studies and
clinical trials, both in terms of efficacy and safety (Table 1)
[14–18]. In this regard, a phase II randomized controlled trial
of poxviral-based PSA-targeted immunotherapy in patients
with metastatic castration-resistant prostate cancer showed
that the treatment was well tolerated and associated with
44% reduction in the death rate [19]. Recently, multi-target
vaccine approaches were tested in vitro, resulting in enhanced
antitumor immune response against hepatocellular carcino-
ma and glioma cell lines [20, 21].

Although several preclinical evidences proved the efficacy
of B7-1-based therapeutic strategy in the induction of
tumor antigen-specific T-cell response, meaningful clinical
improvement has been limited. In addition to the existence
of multiple mechanisms of immune resistance, a possible
explanation for the lack of marked clinical benefits is that B7-
1 and B7-2 also bind CTLA-4 with higher affinity than CD28;
therefore, it is possible that the engagement of CTLA-4 by
B7-1—expressing vaccine could limit its ability to activate
T-cell immunity. This observation opens the door for a
new therapeutic strategy: the specific blockade of CTLA-4
coinhibitory signal.

Several studies demonstrated that the blockade of CTLA-
4 using anti-CTLA-4 antibodies was capable of inducing the
rejection of different types of established tumors in mice, such as colon carcinoma, fibrosarcoma, prostatic carcinoma, lymphoma, and renal carcinoma, along with a memory response [4]. Although effective as monotherapy in the treatment of small and immunogenic tumors, a combination of CTL-4 blockade with other immunotherapeutic strategies is needed to treat large and poorly immunogenic tumors. Combination of CTLA-4 blockade and irradiated tumor vaccine expressing GM-CSF results in tumor rejection and reduction of tumor growth in the B16 melanoma model. Similar results were reported for the poorly immunogenic SM1 mammary carcinoma line and a transgenic model of prostate carcinoma [4, 22]. Moreover, the combination of anti-CTLA-4 with DNA vaccine increased T-cell immune response against melanoma-associated antigens and induced B16 tumor rejection [23]. In the same tumor model, the CTLA-4 blockade combined with CD25+ Treg depletion and vaccination was reported to be effective in inducing tyrosinase-related-protein-2-(TRP-2-) specific CD8+ T cells and in rejecting larger tumor loads [24]. An increased antitumor immunity in B16 melanoma model was reported following CTLA-4 blockade with peptide vaccine and a synthetic oligodeoxynucleotide (ODN) as adjuvant [25]. The use of anti-CTLA-4 along with radiotherapy led to the improvement of survival rate in a mouse model of metastatic breast cancer, whereas CTLA-4 blockade in combination with chemotherapy provided clinical benefits in the murine myeloma model MOPC-315 [26, 27].

The encouraging results obtained in preclinical models led to the development of two fully humanized anti-CTLA-4 antibodies, MDX-010 (ipilimumab), and CP-675,206 (tremelimumab) (Table 1). Ipilimumab is an IgG1 with a plasma half-life of 12–14 days, and it has been approved by the FDA in March 2011 for the treatment of advanced melanoma (Bristol-Myers Squibb, Princeton, NJ, USA). Tremelimumab is an IgG2 with a plasma half-life of approximately 22 days (Pfizer, New York, NY, USA). Both agents are able to recognize human CTLA-4 and block the interaction of CTLA-4 with CD80 or CD86, but their exact mechanism of action is not fully understood. Recently, some authors reported that tremelimumab induces a significant increase in CD8+ cells intratumoral infiltration and that the immune response mediated by this agent is due to a direct activation of effector T cells rather than a depletion of Tregs [28, 29]. Preliminary data about an increase in antigen-specific effector T cells following ipilimumab treatment in combination with vaccine in three melanoma patients are also published [30].

Ipilimumab and tremelimumab were tested in ovarian, breast, prostate, colon carcinoma, and, mainly, in melanoma and renal cell cancer clinical trials [31]. Several early phase II studies evaluated ipilimumab in metastatic melanoma, reporting an objective response rate ranging from 6% to 21% and a disease-control rate of about 30% [32–34]. Recently, a multicenter single arm phase II study evaluated the efficacy and the safety of ipilimumab monotherapy in patients with pretreated advanced melanoma. Patients (n = 155) were treated with ipilimumab at 10 mg/kg and the authors showed that one- and 2-year survival rates were 47.2% and 32.8%, respectively, with a median overall survival of 10.2 months [35]. Moreover, a randomized, double-blind, placebo-controlled, phase II trial of ipilimumab at 10 mg/kg, with or without budesonide, in 115 patients with unresectable stage III or IV melanoma, showed that 2-year survival rate was approximately 40% in each arm [36]. In another randomized, double-blind, multicenter, phase II, dose-ranging study, 217 melanoma patients were randomly assigned to receive ipilimumab at 10 mg/kg (n = 73),

| Costimulatory molecule | Tumor model                                      | Therapeutic strategy                                      | Refs |
|------------------------|-------------------------------------------------|----------------------------------------------------------|------|
| B7-1                   | Metastatic renal carcinoma                      | Vaccination with B7-1-transfected autologous tumor cells in combination with systemic IL-2 | [10–12] |
|                        | Nonsmall cell lung cancer                       | Vaccination with an adenocarcinoma cell line expressing B7-1 and human leukocyte antigen A1(HLA-A1) or A2 | [11] |
|                        | Metastatic colorectal cancer                    | Vaccination with ALVAC vector expressing CEA and B7-1 in combination with chemotherapy | [13] |
|                        | CEA-expressing carcinoma, metastatic carcinoma, prostate cancer | Vaccination with TRICOM vector | [14–17] |
| CTLA-4                 | Metastatic melanoma, metastatic renal cancer, nonsmall cell lung cancer | MDX-010 Ab blockade of CTLA-4 alone or in combination with vaccine, IL-2, and chemotherapy | [32–44] |
|                        | Melanoma, metastatic colorectal cancer, advanced gastric cancer, and esophageal adenocarcinoma | CP-675, 206 Ab blockade of CTLA-4 alone or in combination with chemotherapy | [45–53] |
| PD-1                   | Hematological malignancies                      | CT-011 Ab blockade of PD-1                               | [95] |
|                        | Advanced solid cancer                           | MDX-1106 Ab blockade of PD-1                             | [97] |
|                        | Solid Tumors                                    | MK 3475                                                  | [99] |
|                        | Cancers, multiple indications                   | MDX 1105-01                                              | [99] |

Table 1: Clinical trials of B7:CD28 costimulatory molecules.
3 mg/kg \( (n = 72) \) or 0.3 mg/kg \( (n = 72) \). The authors observed a dose-dependent antitumor effect of ipilimumab, with the best overall response of 11.1% in patients treated with 10 mg/kg [37]. Ipilimumab was also tested in combination with other therapeutic agents such as IL-2, vaccine or chemotherapy, such as dacarbazine [38–42]. In particular, interesting results came from the phase III trial by Hodi et al.; in this study, melanoma patients were randomized to receive ipilimumab 3 mg/kg, with or without a gp100 peptide vaccine, or the vaccine alone. The primary endpoint of the study was the overall survival. The median overall survival was approximately 10.0 months among patients receiving ipilimumab (with or without gp100 vaccine), as compared with 6.4 months among patients receiving gp100 alone [41]. In another phase III study, the administration of ipilimumab (at a dose of 10 mg/kg) in combination with dacarbazine was associated with a significant improvement in overall survival among patients with previously untreated metastatic melanoma [42]. Ipilimumab was also tested in other types of malignancies. In a phase II study on 61 patients affected by metastatic renal cell carcinoma, ipilimumab was administered at a dose of 1 mg/kg or 3 mg/kg; five of 40 patients treated with 3 mg/kg had a partial response [43]. A recent phase II study compared the addition of ipilimumab to carboplatin and paclitaxel chemotherapy in nonsmall cell lung cancer patients. Ipilimumab was administered either concurrently or in a phased schedule after receiving the first two cycles of chemotherapy. Patients treated with ipilimumab plus chemotherapy, in concurrent and sequential regimens, showed an improved overall survival compared with patients receiving chemotherapy alone [44]. Tremelimumab was first evaluated in the treatment of metastatic melanoma. A phase I clinical trials evaluating the maximum-tolerated dose of tremelimumab showed antitumor activity of this drug in melanoma patients [45]. Other phase I/II studies reported SD occurring in about 30% of melanoma patients treated with tremelimumab and an objective antitumor response in 10% of patients [46–48]. A phase II study evaluated the antitumor activity of 15 mg/kg tremelimumab in 246 patients affected by melanoma, reporting an objective response rate of 6.6%, with duration of response ranged from 8.9 to 29.8 months [49]. A phase III trial of tremelimumab in combination with DTIC or temozolomide was recently withdrawn, because of the lack of a survival advantage in the tremelimumab group [50]. Tremelimumab was also tested in cancers others than melanoma, both as monotherapy and in combination therapy, such as metastatic renal cell carcinoma, metastatic colorectal cancer, and advanced gastric and esophageal adenocarcinoma, but not significant clinical improvements were reported [51–53]. The treatment with both ipilimumab and tremelimumab is associated with inflammatory adverse events like rash, diarrhea, colitis, and hypophysitis; this side effect profile could be linked to the potentiation of Th17 cell differentiation following CTLA-4 blockade [54].

2.2 ICOS-L: ICOS. The inducible costimulator (ICOS, CD278) is a costimulatory receptor that is weakly expressed on naïve T cells and quickly upregulated in activated CD4+ and CD8+ T cells. A constitutive expression of ICOS by CD25+CD4+Foxp3+ Tregs has also been reported [55]. The cognate ligand for ICOS is ICOS-L (B7h, B7RP-1, CD275), which is expressed by professional APCs and by peripheral epithelial and endothelial cells following TNF-α stimulation [56]. The ICOS:ICOS-L pathway provide a key costimulatory signal for T-cell proliferation and, mainly, for T-cell survival [57]. Moreover, ICOS regulates development and response of T follicular helper (Tfh), Th1, Th2, Th17 cells and plays roles in the maintenance of memory effector T cells and Tregs homeostasis [57]. The observation that immune defects in CD28 knockout mice can be reverted by crossing them with sanroque mice, which express ICOS constitutively, suggested that the two receptors activated similar intracellular pathways [58]. In fact, ICOS is able to trigger the PI3K/Akt pathway greater than CD28 and to activate the downstream MAPKs cascade [59]. Due to its role in sustaining T-cell activation and effector functions, targeting ICOS:ICOS-L could represent a plausible approach to enhance antitumor immunity. The ICOS-L costimulation, through its expression on tumor cells, was capable of inducing cancer regression in Sa1/N fibrosarcoma and J558 plasmacytoma models [60, 61]. Systemic treatment with murine ICOSL-IgG fusion protein was effective in promoting INF-γ-dependent antitumor immunity in MethA fibrosarcoma and B16F1 melanoma tumor models [62]. Recent data showed an increase of ICOS+CD4+ effector T cells percentage after CTLA-4 blockade in several cancer models. In addition, upon CTLA-4 blockade, this cell population produced greater levels of INF-γ than ICOSlo CD4+ T cells, suggesting that ICOS could be used as a marker for CD4+ effector T-cell response [63–66]. A downregulation of ICOS was shown in colon cancer patients and the expression of ICOS in tumors was associated with a greater survival of melanoma patients [67, 68]. A recent study investigated the role of ICOS in the Tregs in melanoma, demonstrating the selective expression of ICOS on a “hyperactivated” Treg population that strongly inhibits T-cell response through IL-10-mediated APCs suppression [69]. Moreover, ICOS-L was expressed by both cultured and freshly isolated melanoma cells from stage IV melanoma patients and could provide costimulation through ICOS for the activation and expansion of Tregs in the tumor microenvironment, as another mechanism of escape from immune surveillance [70]. Thus, targeting costimulatory and coinhibitory molecules on Tregs might be a promising approach for modulating peripheral tolerance in cancer patients.

2.3 PD-L1/PD-L2:PD-1. Programmed cell death 1 (PD-1) is a negative costimulatory receptor belonging to the B7/CD28 family. PD-1 expression is induced on activated T cells, B cells, monocytes, DCs, and, at low levels, on natural killer T cells (NKT) [71]. Negative costimulatory signals mediated via PD-1 and CTLA-4 are not redundant; in fact PD-1 mainly acts in regulating inflammatory responses in peripheral tissues, whereas CTLA-4 modulates T-cell priming in lymphoid organs. In addition, in contrast to CTLA-4, PD-1 is able to block TCR- and CD28-mediated activation through the recruitment of inhibitory phosphatases, such as SHP-2, which inhibits the induction of PI3K activity [71].
PD-1 has two known ligands belonging to the B7 family: PD-L1 (B7-H1) and PD-L2 (B7-DC). To date, one of the major differences between these ligands concerns their expression pattern. PD-L1 mRNA is broadly expressed in multiple peripheral tissues such as heart, placenta, muscle, fetal liver, spleen, lymph nodes, and thymus; PD-L1 protein has been found in activated T cells, B cells, monocytes, DCs, in endothelial cells and myocardium and can be upregulated following exposure to type I or type II interferon, providing a negative feedback mechanism to dampen immune response [69]. On the contrary, PD-L2 expression is largely restricted to activated macrophages and DCs, but only PD-L2 mRNA can also be observed in the human heart, placenta, lung, and liver [72]. The function of PD-L1 and PD-L2 has been debated, owing to conflicting results about the costimulatory signal provided by the ligands. Opposite results have been obtained using PD-L1 fusion protein and mAbs, but, to date, the accepted opinion is that PD-1/PD-L1 interaction generally produces a negative costimulatory signal [69]. The same controversial results have been reported about PD-L2, with one group demonstrating a negative costimulatory role for this ligand, and another group reporting that PD-L2 was able to stimulate T cells [72]. In vivo data from PD-L2 deficient mice supported a stimulatory function of PD-L2. Anyway, the disagreeing results concerning PD-L1 and PD-L2 roles may be explained by the existence of another receptor able to bind these ligands that have positive costimulatory functions, like CD28 [73].

PD-L1 aberrant expression has been reported in many human cancers, such as glioblastoma, melanoma, and cancers of the head and neck, lung, ovary, colon, stomach, kidney, and breast [74, 75]. Moreover, in several follow-up studies, the expression of PD-L1 correlates with a poor prognosis of patients [76–82]. Based on these experimental evidences, PD-L1 blockade has been proposed for cancer immunotherapy. Two independent studies have shown that forced expression of PD-L1 in the murine myeloma cell line P815 render them more resistant to in vitro cytolyis and less susceptible to rejection than control when inoculated in mice [83, 84]. In addition, the treatment with anti-PD-L1 mAbs was capable of inhibiting the growth of P815-PD-L1 in vivo [84]. PD-1 blockade was able to restore the antitumor immunity to accelerate tumor eradication in murine squamous cancer cell line SCCVII, in P815 cell line and to block both CT26 colon carcinoma metastasis to the lung and B16 melanoma metastasis to the liver [85–87]. In vivo studies in these tumor models examined the combination of anti-PD-1 mAb with GM-CSF-secreting tumor cell vaccine and reported that the administration of anti PD-1 mAb enhanced the efficacy of vaccine increasing number and activity of tumor-specific CD8+ T cells [88]. A recent study reported that the combination of PD-1 blockade and NKT cell activation results in increased antitumor responses in a melanoma model [89]. A reduced number of Tregs at the tumor site was observed after the treatment with anti-PD-1 mAb and the Toll-like receptor agonist CpG, suggesting that it could be another mechanism by which PD-1 blockade exerts antitumor effects [90]. The expression of PD-L1 on DCs is also able to block antitumor T-cell response; myeloid DCs expressing PD-L1 isolated from ovarian cancer poorly stimulated T cells and PD-L1 blockade could revert this scenario [91]. In addition, the anti-PD-L1 therapy was observed to revitalize "exhausted" antiviral CD8+ T cells in animals with chronic viral infections [92]. The promising results in preclinical models have led to the development of two humanized antibodies against PD-1 receptor that block its interaction with PD-L1:CT-011 and MDX-1106 (Table 1). A preclinical study evaluated the combination of CT-011 with low dose of cyclophosphamide and with a tumor vaccine; the authors reported the complete regression of established tumors in most of the animals treated [93]. Benson et al. reported that CT-011 enhances NK-cell migration toward malignant plasma cells in multiple myeloma [94]. To date, only phase I clinical trials have been conducted to evaluate both efficacy and safety of these two agents. In a phase I trial enrolling 17 patients with advanced hematological malignancies, the treatment with CT-011 at doses ranging from 0.2 to 6 mg/kg led to clinical improvement in 33% of patients [95]. Recently, the administration of CT-011 in combination with autologous dendritic cell/myeloma fusion-vaccine was demonstrated to stimulate T-cell responses after vaccine administration [96]. The efficacy of MX-1106 was evaluated in a phase I study enrolling 39 patients with advanced solid cancers (melanoma, colorectal cancer, castrate-resistant prostate cancer, nonsmall-cell lung cancer, and renal cell carcinoma) obtaining very promising results; phase II and III trials are under evaluation [97]. In particular, it will be interesting to evaluate the combination of anti-PD1 with other agents, such as anti-CTLA-4 mAb, vaccines, and chemotherapy. Several phase II clinical trials are testing the safety and the efficacy of these two PD-1 antibodies in several types of cancer [98]. MK-3475 and MDX-1105-01 are other two antibodies against PD-1 and PD-L1, respectively, which are currently being investigated in phase I clinical trials (Table 1) [99].

2.4. HVEM:BTLA/CD160. The B- and T-lymphocyte attenuator (BTLA) is another member of the B7/CD28 family acting as a negative costimulatory receptor [100]. The constitutive expression of BTLA has been reported, at low levels, on naïve B and T cells, Thx, macrophages, DCs, NKT cells, and natural killer cells (NK), but unlike CTLA-4 and PD-1, BTLA is not expressed on Tregs [100]. BTLA expression is upregulated following T-cell activation [101]. Moreover, like PD-1, BTLA seems to have a role in inducing CD8+ T-cell exhaustion during chronic viral response. The herpes virus entry mediator (HVEM), a member of TNFR superfamily, has been identified as BTLA ligand. HVEM expression is high in naïve T and B cells, but it decreases during T-cell activation. HVEM is also expressed on DCS, Tregs, monocytes, NK cells, and neutrophils, and in nonhematopoietic cells, such as parenchymal cells [100].

In addition to BTLA, HVEM binds also CD160, another member of the B7/CD28 family. CD160 is highly expressed on CD56dimCD16 NK cells, NKT cells, γδ T cells, CD8+CD28− T cells, a small subset of CD4+ cells and intestinal intraepithelial T cells (IEL) [100].
HVEM also interacts with LIGHT (described below in the text) and lymphotoxin alpha (LTα) of TNFR family, being the unique example of a direct interaction between the two families [102]. Therefore, HVEM is considered a molecular switch, because of its ability to regulate the immune response depending on which cognate ligand binds. In contrast to LIGHT and LTα, engagement, which generally delivers positive costimulatory signals, HVEM engagement of BTLA and CD160 provides negative costimulatory signals to T cells [100, 102]. The role of BTLA as a negative costimulatory receptor has been shown by the phenotype of BTLA deficient mice, which were more susceptible to develop autoimmune disorders, and by the in vitro observation that anti-BTLA agonists drive negative signals to T cells [102]. The engagement of BTLA results in the inhibition of CD3/CD28 T-cell activation. BTLA signals through the recruitment of SHP-2 phosphatase, but the downstream target of SHP-2 is unclear. Anyway, recent studies showed that triggering BTLA signaling in B cells resulted in blocking B-cell proliferation through the inhibition of phosphorylation of some transcription factors like NF-kB [103].

The similarity between BTLA and PD-1 signaling could justify a possible use of BTLA blockade to enhance antitumor immunity. The expression of BTLA was found in chronic lymphocytic leukemia/small lymphocytic lymphoma [104]. Moreover, soluble BTLA seems to enhance antitumor efficacy of the HSP70 vaccine in murine TC-1 cervical cancer mice [105]. Recently, a study by Derré et al. demonstrated the potentiality of targeting BTLA for cancer immunotherapy, reporting that BTLA is expressed on tumor antigen-specific CD8+ T cells from melanoma patients and that this molecule inhibits their fully functionality; following the vaccination with CpG adjuvants, the authors observed a downregulation of BTLA, with a partial recovery of CD8+ T cells functionality [106]. BTLA-HVEM blockade showed antitumor effects in murine TC-1 cervical cancer model in vivo, resulting in downregulation of IL-10 and TGF-beta and in activation of dendritic cells in IL-12- and B7-1-dependent manner. Anyway, BTLA-HVEM blockade alone was not effective in eradicating the tumor, whereas the combination with HSP70 vaccine improved antitumor immunity by increasing IL-2 and INF-γ production and decreasing IL-10, TGF-beta, and Foxp3 transcription levels in the tumor microenvironment [107]. The evidences supporting a negative costimulatory function for CD160 come from in vitro studies, because CD160 deficient mice have not been generated. CD160 agonists strongly inhibited CD4+ T-cell proliferation and cytokines production and reduced INF-γ secretion by NK cell line [108]. Recently, Cai et al. reported a strong inhibition of CD3/CD28-induced T-cell activation after the use of CD160 agonists, but the downstream intracellular pathways involved are not known [109]. Indeed, Liu et al. reported that CD160 is expressed in B-cell chronic lymphocytic leukemia, in which its engagement mediates survival and growth signals. In fact, CD160 activation was associated with upregulation of antiapoptotic genes Bcl-2, Bcl-xL and Mcl-1 and, consequently, with reduced mitochondrial membrane potential collapse and cytochrome c release. CD160 engagement also induced cell cycle progression and proliferation [110]. A recent study examined the expression of CD160 in 811 cases of B-cell lymphoproliferative disorders (B-LPD). The authors showed that CD160 was expressed in 98% of chronic lymphocytic leukemia (CLL) cases, 100% of hairy cell leukemia (HCL) cases, 15% of mantle cell lymphoma (MCL) in the leukemic phase, and 16% of other B-LPD cases, whereas it was absent in the normal B-cell lineage [111]. Recently, Chabot et al. suggested a role for CD160 in tumor neoangiogenesis. CD160 was expressed on newly formed blood vessels in human colon carcinoma and mouse B16 melanoma, but not in the healthy vessels. Treatment with anti-CD160 monoclonal antibody CL1-R2 in combination with cyclophosphamide chemotherapy resulted in the regression of tumor vessels in B16 melanoma-bearing mice [112]. Further studies are needed to clarify this pathway so as to design potential CD160/BTLA-based antitumor therapeutic strategies.

2.5. B7-H3 and B7-H4. B7-H3 and B7-H4 (B7x, B7s1) are two of the newer members of the B7-family. B7-H3 expression has been found to be inducible on T cells, NK cells and APCs [113]. B7-H3 is also broadly expressed on osteoblasts, fibroblasts, and epithelial cells, as well as in liver, lung, bladder, testis, prostate, breast, placenta, and lymphoid organs [113]. To date, only one potential receptor of B7-H3 on activated T cells named TL1-T2 has been identified [113]. There are conflicting data about the functions mediated by B7-H3, as both stimulatory and inhibitory properties have been reported. Initial studies described B7-H3 as a positive costimulatory molecule which enhanced the proliferation of both CD4+ and CD8+ T cells, the induction of cytotoxic T lymphocytes (CTLs) and the production of INF-γ. By contrast, other studies suggested an opposite role for B7-H3, showing that it is able to inhibit T-cell activation and cytokines production, like IL-2 [114]. Moreover, B7-H3 blockade with antagonistic mAbs enhanced T-cell proliferation in vitro and worsened the experimental autoimmune encephalomyelitis (EAE) in vivo, an autoimmune disorder observed also in B7-H3 deficient mice [114]. Because of these controversial results, the possible existence of additional receptors for B7-H3 has been taken into consideration.

Recently, several works reported B7-H3 expression in different human cancers, as reviewed by Loos et al. The double stimulatory and inhibitory nature of B7-H3 signaling also appeared in murine cancer models and in human cancers. The authors showed that B7-H3 expression is associated both to favorable and adverse clinicopathologic features [113]. Due to its immunomodulatory ability, B7-H3 blockade could be a potential anticancer immunotherapy, but the controversial findings about its role remain to be elucidated.

B7-H4 mRNA is broadly expressed in the peripheral tissues, whereas protein expression is restricted to activated B cells, T cells, and monocytes [115]. To date, the cognate receptor of B7-H4 on activated T cells remained unclear, although BTLA has been reported as a possible receptor. Unlike B7-H3, which shows opposite functions, B7-H4 mediates a negative costimulatory signal [116]. B7-H4 strongly inhibited T-cell proliferation and IL-2 secretion, and its blockade with antagonistic mAbs resulted in in vitro...
enhanced T-cell response and \textit{in vivo} exacerbation of EAE [115, 116].

Several studies reported the expression of B7-H4 in many human cancers, such as nonsmall cell lung cancer, ovarian cancer, prostate cancer, breast cancer, and renal cancer [75]. Recent studies indicate that B7-H4 could be a potential diagnostic/prognostic marker and/or therapeutic target for several cancers. In fact, B7-H4 expression was found to correlate with stage, pathological types, and biological behavior of many tumors, as shown by retrospective analyses on 13 types of human cancers. Moreover, the expression of B7-H4 reverse correlated with the survival of patients in most cancer analyzed [117]. A recent study by Quandt et al. demonstrated that the overexpression of B7-H4 in melanoma cells impaired the antitumor immune response by decreasing IFN-\(\gamma\), TNF-\(\alpha\), and IL-2 production [118].

In ovarian cancer, the inhibitory role of B7-H4 might be due to B7-H4 expression on tumor-associated macrophages (TAMs). Kryczek et al. showed that B7-H4-expressing TAMs could block activation of T cells in the setting of ovarian cancer. B7-H4 expression in TAMs was upregulated by IL-6 and IL-10 present in the tumor microenvironment, whereas its expression was inhibited by GM-CSF and IL-4. It has been shown that Treg cells induced APCs to produces IL-10 and IL-6, providing a new mechanism by which Tregs exert their suppressive action. B7-H4 blockade by antisense oligonucleotides restored T-cell antitumor immune response and led to tumor regression \textit{in vivo} [119].

Recently, Qian et al. reported the development of a monoclonal antibody to B7-H4 and preliminary data showed that it could effectively inhibit the activity of B7-H4, promoting the growth of T cells and the secretion of IL-2, IL-4, IL-10, and IFN-\(\gamma\) [120]. Based on these preliminary data, the blockade of B7-H4 could be an attractive opportunity to enhance antitumor immunity in a subset of human cancers.

3. The TNF:TNFR Family

3.1. CD40L:CD40. CD40 receptor and its ligand CD40L (CD154) were the first members belonging to the TNF:TNFR family to be identified [121]. CD40 expression has been originally found on B cells [122], but it is also expressed on DCs, monocytes, platelets, macrophages as well as myofibroblasts, fibroblasts, epithelial, and endothelial cells [121]. CD40L is expressed on activated T and B cells, by platelets, monocytes, NK cells, mast cells and basophils, where CD40L is induced following proinflammatory stimuli [121]. The engagement of CD40 by CD40L on APCs has been shown to promote cytokines production and upregulation of costimulatory molecules, crucial events for T-cell activation, and differentiation [123]. CD40L:CD40 signaling in B cells is also important for the generation of long-lived plasma cells and memory B cells, as well as for their survival. CD40 intracellular signaling is mediated by the recruitment of TNFR-associated factors (TRAFs), which in turn activate different pathways, such as the canonical and noncanonical NF-\(\kappa\)B pathway, MAPKs, PI3K and the phospholipase Cy pathway [121].

CD40/CD40L pathway is crucial for the development of antitumor immunity. CD40L blockade resulted in lacking of protective immune response following administration of a GM-CSF-expressing B16 melanoma cells vaccine. In addition, low expression of CD40L was sufficient to induce a long-lasting antitumor immune response via CTLs in a small number of cancers [4, 121]. The combination of CD40L expression with other immunomodulators (IL-2, GM-CSF, and INF-\(\gamma\)) has been found to promote antitumor immunity in several cancer models. Gene therapy approach with the use of recombinant adenovirus encoding CD40L was also effective in colorectal, lung, and melanoma cancer models. An early study reported that the use of CD40 agonistic antibodies triggered CTL-4 responses in a lymphoma system, with the consequent tumor eradication [4, 124]. Recently, the use of activators of both adaptive and innate immunity, such as CD40 agonists and Toll-like receptor (TLR) agonists, induced antitumor-specific immunity in many tumor models [125]. Currently, the combination of CD40 tumor therapy with other approaches, such as cancer vaccines, chemotherapy, radiation, CTLA blockade, TLR agonists, and cytokines, is becoming overriding [125–127].

Another aspect to take into consideration is the direct effect of CD40:CD40L pathway on tumor cells. Elgueta et al. reviewed that CD40 is broadly expressed in several tumors, such as melanoma, prostate cancer, lung cancer, as well as carcinoma of nasopharynx, bladder, cervix and ovary, Hodgkin’s and non-Hodgkin’s lymphoma, multiple myeloma, and acute myeloid leukemia. The engagement of CD40 on tumor cells can provide growth arrest and apoptosis of malignant cells, dependently on type of malignancies and the microenvironment [121].

To date, three humanized CD40 agonistic antibodies have been developed: CP-870,893, SGN-40, and HCD 122 (Table 2). CP-870,893 is a fully human, IgG2 antibody that selectively binds to CD40. It enhances the expression of MHC class II, CD54, CD86 and CD23 on human B cells \textit{in vitro}. CP-870,893 also enhances dendritic cell activity as demonstrated by secretion of IL-12, IL-23, and IL-8, by the upregulation of CD86 and CD83, and by the capacity to prime T cells to secrete IFN-\(\gamma\) [128, 129]. Results from a phase I study showed that administration of CP-870,893 was associated with early signs of clinical efficacy, especially in patients with melanoma [130]. The same authors reported that weekly infusions of this agonist CD40 antibody were associated with little clinical activity in advanced cancer patients [131]. SGN-40 (Dacetuzumab) is a humanized anti-CD40 monoclonal antibody with multiple mechanisms of action. In non-Hodgkin lymphoma, Dacetuzumab activates two distinct proapoptotic signaling pathways; on the one hand, it constitutively activates the NF-\(\kappa\)B and MAPK signaling pathways producing the sustained downregulation of the oncprotein B-cell lymphoma 6, which loss results in c-Myc downregulation and activation of early B-cell maturation, concomitant with reduced proliferation and cell death. On the other hand, dacetuzumab induces the expression of the proapoptotic p53 family member TAp63\(\alpha\) and downstream proteins associated with the intrinsic and extrinsic apoptotic machinery [132]. \textit{In vitro}, dacetuzumab exhibited
antitumor activity against several B-cell lymphoma and multiple myeloma (MM) cell lines, and induced direct apoptosis as well as the engagement of effective antibody-dependent cell-mediated cytotoxicity (ADCC) [133]. Early clinical trials have evaluated the pharmacokinetics, safety and efficacy of dacetuzumab in patients with relapsed/refractory B-cell lymphomas, MM and chronic lymphocytic leukemia [134–136]. Dacetuzumab resulted in modest antitumor activity in B-cell lymphomas and, to a lesser extent, in MM. In chronic lymphocytic leukemia dacetuzumab showed modest activity as monotherapy, while better results were obtained by using combination therapy with lenalidomide [137]. Dacetuzumab showed promising results as monotherapy, while better results were obtained by using combination therapy with lenalidomide [137]. Dacetuzumab is currently in multiple phase II trials for the treatment of myeloma and diffuse large cell lymphoma. HCD122 is a human IgG1 monoclonal antibody. In B-cell chronic lymphocytic leukemia, HCD122 exerts antitumor activity by killing leukemia cells through ADCC and inhibiting CD40L-induced survival and proliferation of tumor cells [138]. HCD 122 is in a phase I trial for the treatment of multiple myeloma and B-cell chronic lymphocytic leukemia [121].

3.2. 4-1BBL:4-1BB. 4-1BB is an inducible costimulatory receptor expressed on activated CD4+ and CD8+ T cell, NKT, NK cells, DCs, macrophages, eosinophils, neutrophils, and mast cells, as well as Tregs [139, 140]. In the most cases, 4-1BB is induced on the cellular surface following activation, except for APCs and Tregs, where its expression is constitutive [139]. The ligand of 4-1BB is 4-1BBL, which is expressed on activated professional APCs [139]. 4-1BB-4-1BBL pathway seems to amplify the existing costimulatory signals, even if the engagement of 4-1BB in the presence of a strong TCR signaling can induce IL-2 production in a CD28-independent manner [141]. Following stimulation with its ligand, 4-1BB provides costimulatory signals to both CD4+ and CD8+ T cells, with a greater effect on the expansion of CD8+ due to the upregulation of antiapoptotic genes, such as bcl-XL and bfl-1. 4-1BB signals are mediated by the activation of NF-κB, c-Jun and p38 downstream pathways [142]. 4-1BB has also a role in activation of DCs, inducing IL-6 and IL-12 production and upregulating B7 costimulatory molecules [142]. 4-1BB plays roles in activating non-T-cells other than DCs, such as monocytes, B cells, mast cells, NK cells, and neutrophils and its engagement is associated with cellular proliferation, cytokine induction, bactericidal activity and sustenance of T-cell effector functions [139].

Targeting of 4-1BB:4-1BBL pathway in cancer reveals itself as a promising approach. The adoptive transfer of ex vivo 4-1BB- and CD28-costimulated T cells induced antitumor immune response in some preclinical studies [143, 144]. Nevertheless, this approach seems not to be a practicable way, because of the limits of this application in humans, such as the small number of ex vivo generated T cells and the risk of transformation of T cells during in vitro culture [142]. 4-1BB agonistic antibodies as antitumor therapy were broadly tested in several animal models with encouraging results. Melero et al. reported that the intraperitoneal injection of an antimurine 4-1BB mAb resulted in the eradication of established P815 mastocytoma and Ag104A sarcoma in mice [145]. Driessens et al. reviewed of subsequent studies that demonstrated the efficacy of anti-4-1BB- or 4-1BBL-expressing tumor cells vaccines in inducing specific antitumor T-cell response, suppression of tumor growth and regression of preestablished tumors in different animal models [4]. Therapeutic effects of agonistic anti-4-1BB mAb are due to enhanced natural killer (NK) and CD8+ T-cell activation and IFN-γ production [140]. The current direction toward which 4-1BB-directed anticancer immunotherapy is moving is the use of anti-4-1BB mAbs in combination with other therapeutic approaches, such as antitumor necrosis factor-related apoptosis inducing ligand (TRAIL), CD40 mAbs, intratumoral delivery of IL-12 gene, DC vaccines, CTLA-4 blockade, anti-CD4 therapy, chemotherapy, and radiotherapy [4, 146, 147]. To date, one agonistic anti-4-1BB-humanized mAb BMS-663513 has been developed and the functional effects were demonstrated on human and monkey T cells and peripheral blood mononuclear cells (PBMCs), where IFN-production was enhanced compared to controls (Table 2) [148]. BMS-663513 is under evaluation in several phase I and II trials in patients with solid tumors, showing clinical activity. A phase II randomized study in melanoma patients with stage IV disease was stopped due to the occurrence of hepatitis [98, 148, 149].

3.3. OX-40:OX-40L. OX-40 is an inducible costimulatory receptor expressed on activated CD4+ and CD8+ T cell, but also on activated Tregs, NKT cells, NK cells, and neutrophils

| Costimulatory molecule | Tumor model | Therapeutic strategy | Refs |
|------------------------|-------------|---------------------|-----|
| CD40 | Melanoma, Advanced cancers | CP-870,893 agonistic Ab anti-CD40 | [130, 131] |
| CD40 | Myeloma, B-cell lymphoma, diffuse large cell lymphoma | SGN-40 agonistic Ab anti-CD40 | [134–136] |
| CD40 | Multiple myeloma, B-cell chronic lymphocytic leukemia | HCD 122 agonistic Ab anti-CD40 | [121] |
| 4-1BB | Solid tumors | BMS-663513 agonistic Ab anti-4-1BB | [148] |
| OX40 | Metastatic prostate cancer | Agonistic Ab anti-OX40 | [99] |
| GITR | Melanoma | TRX518 | [99] |
| CD30 | CD30-positive lymphoma | Brentuximab vedotin Ab-drug conjugates anti-CD30 | [179–182] |
OX-40L expression is induced on professional APCs, as well as on T cells, with the aim of amplifying T-cell responsiveness during T-cell/T-cell interactions [150]. In addition to APCs, other cell types can induce OX-40L expression, such as Langerhans cells, mast cells, NK cells, endothelial cells, and smooth muscle cells [150]. Based on experimental evidences from OX-40 deficient mice, it has been reported that this receptor promotes effector T-cell proliferation and survival, cytokines production, as well as the generation, and the maintenance of memory T cells [150]. Moreover, OX-40 inhibits Treg functions and counteracts the generation of inducible Tregs [150]. OX-40 seems to act as a late positive costimulatory receptor, which goes on after CD28 signal, in a sequential manner [151]. The pro-survival activity of OX-40 is in part due to its ability to upregulate antiapoptotic genes of the Bcl-2 family. In fact, LIGHT is a member of TNF family [101]. LIGHT expression has been reported on activated T cells, on immature DCs, on APCs, other cell types can induce LIGHT expression, and it will be tested in future clinical trials [99].

3.5. CD70:CD27. CD70 is another costimulatory receptor belonging to the TNF family, and it is expressed on naïve T and B cells and on NK cells [151]. CD70 has been identified as CD27 ligand and its expression is restricted to APCs [151]. The engagement of CD27 by CD70 promotes a positive costimulatory signaling, resulting in T-cell proliferation and survival, maybe in concert with CD28 [151]. Recently, a critical role for CD70 in priming CD8+ T cells has been demonstrated [165]. The stimulatory role of this pathway is confirmed by the observation that CD70 and CD27 transgenic mice developed autoimmune diseases [166]. Like other members of the TNFR family, CD27 signaling is mediated by the recruitment of TRAF proteins [167]. Targeting CD27 could represent an attractive strategy in the field of cancer immunotherapy. Driessens et al. reviewed about early studies reporting that the overexpression of CD70 promoted cancer elimination through the activation of T cells and NK cells [4]. In addition, the potential of costimulatory ligand CD70 to boost DC-based vaccine capacity to evoke effective
CD8+ T-cell immunity has been explored [168]. Glouchkova et al. suggested that the modulation of the CD70/CD27 pathway might represent a novel therapeutic approach for enhancing the antileukemic response in B-cell precursor acute lymphoblastic leukemia [169]. Recently, agonistic anti-CD27 antibodies has shown to be effective as monotherapy in reducing the outgrowth of experimental lung metastases and established subcutaneous melanoma tumors in vivo [170]. In addition to CD70 agonists, the soluble form of CD70 has been evaluated as positive adjuvant in a glioblastoma model [171]. The aberrant expression of CD70 in a broad range of hematological malignancies and in some solid tumors has led to the development of CD70-specific T cells, having a CAR receptor consisting of CD27 fused to the CD3- chain. Recently, adoptively transferred CD70-specific T cells have been found to induce regression of established murine xenografts through the recognition of CD70-expressing tumor cells [172].

3.6. GITR: GITR. Glucocorticoid-induced TNFR-related protein (GITR) is a costimulatory receptor expressed on activated T cells and, constitutively, on Tregs [173]. Its ligand GITRL is expressed at low levels on APCs, but it gets induced following TLR stimulation [173]. Several studies have reported that GITR signaling promotes the proliferation of naïve T cells and cytokines production through the recruitment of TRAF proteins and the activation of downstream pathways [174]. Moreover, one of the first described GITR function was the ability to protect T cells from activation-induced cell death. Controversial data have been reported about the regulation of Treg functions by GITR. In fact, experimental evidences suggest both an inhibitor and a stimulatory role for GITR. The modulation of GITR pathway is an intriguing therapeutic possibility. The treatment with GITR-expressing adenovirus vector has been shown to be able to induce T-cell response and to reduce tumor size in mice inoculated with B16 tumor cells [175]. Nishikawa et al. reported that triggering GITR through GITRL-expressing plasmid resulted in the inhibition of tumor growth in a CMS5 sarcoma model. The protection of CD8+ T cell against Treg-mediated suppression was also observed by the authors [176]. The use of GITR agonistic antibody (clone DTA-1) is also effective in stimulating antitumor immunity in vivo [174]. Recently, Zhou et al. suggested that the antitumor effect of anti-GITR antibody was dependant on its ability to positive costimulate T cells rather than to suppress Treg functions, but the question is still debated [177]. Last year, a clinical study of an agonist anti-GITR antibody (TRX518) in melanoma was started but the trial was put on hold in March because of a major business setback of the company that makes the antibody (Table 2) [99].

3.7. CD30L:CD30. CD30 receptor is an inducible costimulatory receptor expressed on activated and memory T cells following TCR/CD28 or IL-4 stimulation [178]. The ligand of CD30 is CD30L, which is expressed on activated T cells, as well as on macrophages, dendritic cells, and B cells [178]. CD30L/CD30 signaling seems to be involved in Th1 and Th2 cell responses and plays a critical role in Th17 differentiation [178]. The costimulatory signal provided by CD30L:CD30 is not yet at all clear, but it seems to be involved in the peripheral costimulation, mainly supporting T-cell survival, with overlapping features of OX-40 and 4-1BB pathways [167]. Due to the expression of CD30 on all malignant Hodgkin and Reed-Sternberg cells (HRS), this receptor represents an important target for the immunotherapy of hematological malignancies. SGN-35 (brentuximab vedotin) is an anti-CD30 antibody that has been modified by the addition of a dipeptide linker to permit attachment of microtubule polymerization monomethylauristatin E (MMAE) (Table 2) [179]. SGN-35 has been evaluated in phase I dose-escalation study in 45 patients with relapsed or refractory CD30-positive hematologic malignancies and the maximum tolerated dose was determined to be 1.8 mg/kg [180]. In a pivotal phase II study of SGN-35, 102 patients with relapsed or refractory Hodgkin lymphoma were treated with 1.8 mg/kg dose of SGN-35 every three weeks. A reduction in tumor volume was observed in 95% of patients and the overall response rate (ORR) was 75% [181]. The efficacy of SGN-35 has been also evaluated in a phase II single-arm study in 58 patients with anaplastic large cell lymphoma. The authors reported that the ORR was 86% [182]. A multicenter randomized phase III trial of SGN-35 (AETHERA) in posttransplant classical Hodgkin lymphoma patients at high risk for recurrence was started in April 2010 and it should be completed in June 2013. In the light of these impressive result, the FDA approved SGN-35 for the treatment of Hodgkin lymphoma in August 2011. The high efficacy of this antibody-drug conjugate could be due to the fact that cytotoxic effect of MMAE targets not only CD30-expressing HRS cells, but also the immune suppressive Tregs present in the tumor microenvironment because of a bystander effect; moreover, SGN-35 delivers itself an additional apoptotic signal, mainly in anaplastic large cell lymphoma cells [179].

4. Conclusions
Improving the knowledge of T costimulatory and coinhibitory pathways reached over the past decade shed light on the central roles that these molecules play in the generation of an effective immune response. Many tumors escape from immune surveillance through the downregulation of positive costimulatory molecules and the upregulation of coinhibitory signals. Blockade of coinhibitory pathway on the one hand and the stimulation of the positive signals on the other hand have been found to enhance antitumoral immunity, both alone and in combination with traditional therapy in preclinical and clinical trials. Further studies are necessary to evaluate the safety and the efficacy of these approaches before using them in the clinical practice.

Acknowledgments
Work described in this paper was supported in part by MIUR PRIN 2008 Project to E. Alesse. D. Verzella is supported by the Ph.D. Program in Experimental Medicine, and M. Fischietti is supported by the Ph.D. Program in Biotechnology.
References

[1] M. K. Jenkins and R. H. Schwartz, “Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo,” Journal of Experimental Medicine, vol. 165, no. 2, pp. 302–319, 1987.

[2] J. D. Schwartz, X. Zhang, S. G. Nathenson, and S. C. Almo, “Structural mechanisms of costimulation,” Nature Immunology, vol. 3, no. 5, pp. 427–434, 2002.

[3] R. H. Schwartz, “T cell anergy,” Annual Review of Immunology, vol. 21, pp. 305–334, 2003.

[4] G. Driessens, J. Kline, and T. E. Gajewski, “Costimulatory and coinhibitory receptors in anti-tumor immunity,” Immunological Reviews, vol. 229, no. 1, pp. 126–144, 2009.

[5] A. S. G. Salama and F. S. Hodi, “Cytotoxic T-lymphocyte-associated antigen-4,” Clinical Cancer Research, vol. 17, no. 14, pp. 4622–4628, 2011.

[6] J. Song, F. T. Lei, X. Xiong, and R. Haque, “Intracellular signals of T cell costimulation,” Cellular & Molecular Immunology, vol. 5, no. 4, pp. 239–247, 2008.

[7] K. Ying, Y. Onishi, P. Prieto-Martin et al., “CTLA-4 control over Fpox3 regulatory T cell function,” Science, vol. 322, no. 5899, pp. 271–275, 2008.

[8] S. Read, R. Greenwald, A. Iczue et al., “Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo,” Journal of Immunology, vol. 177, no. 7, pp. 4376–4383, 2006.

[9] Z. Zippelius, P. Batard, V. Rubio-Godoy et al., “Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance,” Cancer Research, vol. 64, no. 8, pp. 2865–2873, 2004.

[10] S. J. Antonia, J. Seigne, J. Diaz et al., “Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma,” Journal of Urology, vol. 167, no. 5, pp. 1995–2000, 2002.

[11] L. E. Raez, P. A. Cassileth, J. J. Schleselman et al., “Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2800–2807, 2004.

[12] M. Fishman, T. B. Hunter, H. Soliman et al., “Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma,” Journal of Immunotherapy, vol. 31, no. 1, pp. 72–80, 2008.

[13] H. L. Kaufman, H. J. Lenz, J. Marshall et al., “Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer,” Clinical Cancer Research, vol. 14, no. 15, pp. 4583–4588, 2008.

[14] J. L. Marshall, J. L. Gilley, P. M. Arlen et al., “Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas,” Journal of Clinical Oncology, vol. 23, no. 4, pp. 720–731, 2005.

[15] H. L. Kaufman, S. Cohen, K. Cheung et al., “Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors,” Human Gene Therapy, vol. 17, no. 2, pp. 239–244, 2006.

[16] R. S. DiPaola, M. Plante, H. Kaufman et al., “A phase I trial of pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer,” Journal of Translational Medicine, vol. 4, article no. 1, 2006.

[17] H. L. Kaufman, S. Kim-Schulze, K. Manson et al., “Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer,” Journal of Translational Medicine, vol. 5, article no. 60, 2007.

[18] S. Yang and J. Scholm, “Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells,” Cancer Immunology, Immunotherapy, vol. 58, no. 4, pp. 503–515, 2009.

[19] P. W. Kantoff, T. J. Schuetz, B. A. Blumenstein et al., “Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1099–1105, 2010.

[20] G. Li, X. Wu, F. Zhang et al., “Triple expression of B7-1, B7-2 and 4-IBB enhanced antitumor immune response against mouse H22 hepatocellular carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 4, pp. 495–703, 2011.

[21] D. Pan, X. Wei, M. Liu et al., “Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells,” Neurological Research, vol. 32, no. 5, pp. 502–509, 2010.

[22] A. A. Hurwitz, B. A. Foster, E. D. Kwon et al., “Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade,” Cancer Research, vol. 60, no. 9, pp. 2444–2448, 2000.

[23] P. D. Gregor, J. D. Wolchok, C. R. Ferrone et al., “CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmune to self antigens in animal and cellular model systems,” Vaccine, vol. 22, no. 13-14, pp. 1700–1708, 2004.

[24] R. P. M. Suttermuller, L. M. Van Duivenvoorde, A. Van Elsas et al., “Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25 regulatory T cells in anti-tumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses,” Journal of Experimental Medicine, vol. 194, no. 6, pp. 823–832, 2001.

[25] E. Davila, R. Kennedy, and E. Cells, “Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade,” Cancer Research, vol. 63, no. 12, pp. 3281–3288, 2003.

[26] S. Demaria, N. Kawashima, A. M. Yang et al., “Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer,” Clinical Cancer Research, vol. 11, no. 2, pp. 728–734, 2005.

[27] M. B. Mokyr, T. Kalinichenko, L. Gorelik, and J. A. Bluestone, “Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice,” Cancer Research, vol. 58, no. 23, pp. 5301–5304, 1998.

[28] S. Khan, D. J. Burt, C. Ralph, F. C. Thistlethwaite, R. E. Hawkins, and E. Elkord, “‘Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells,” Clinical Immunology, vol. 138, no. 1, pp. 85–96, 2011.

[29] R. R. Huang, J. Jalil, J. S. Economou et al., “CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans,” Clinical Cancer Research, vol. 17, no. 12, pp. 4101–4109, 2011.
Journal of Biomedicine and Biotechnology

[30] J. Yuan, M. Adamow, B. A. Ginsberg et al., “Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 40, pp. 16723–16728, 2011.

[31] A. J. Korman, K. S. Peggs, and J. P. Allison, “Checkpoint Blockade in Cancer Immunotherapy,” Advances in Immunology, vol. 90, pp. 297–339, 2006.

[32] A. V. Maker, J. C. Yang, R. M. Sherry et al., “Intrapatent dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma,” Journal of Immunotherapy, vol. 29, no. 4, pp. 455–463, 2006.

[33] G. Q. Phan, J. C. Yang, R. M. Sherry et al., “Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8372–8377, 2003.

[34] J. S. Weber, E. M. Hersh, M. Yellin et al., “The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma,” Journal of Clinical Oncology, vol. 25, no. 18, p. 8523, 2007.

[35] O. Hamid, K. Chin, J. Li et al., “Dose effect of ipilimumab in patients with advanced melanoma: results from a phase II, randomized, dose-ranging study,” Journal of Clinical Oncology, vol. 26, p. 489s, 2008.

[36] S. I. O’Day, M. Maio, V. Chiariion-Sileni et al., “Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study,” Annals of Oncology, vol. 21, no. 8, pp. 1712–1717, 2010.

[37] J. Weber, J. A. Thompson, O. Hamid et al., “A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma,” Clinical Cancer Research, vol. 15, no. 17, pp. 5591–5598, 2009.

[38] J. D. Wolchok, B. Neyns, G. Linette et al., “Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study,” The Lancet Oncology, vol. 11, no. 2, pp. 155–164, 2010.

[39] A. V. Maker, G. Q. Phan, P. Attia et al., “Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase II/I study,” Annals of Surgical Oncology, vol. 12, no. 12, pp. 1005–1016, 2005.

[40] E. M. Hersh, S. J. O’Day, J. Powderly et al., “A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma,” Investigational New Drugs, vol. 29, no. 3, pp. 489–499, 2011.

[41] F. S. Hodi, S. J. O’Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010.

[42] C. Robert, L. Thomas, I. Bondarenko et al., “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” New England Journal of Medicine, vol. 364, no. 26, pp. 2517–2526, 2011.

[43] J. C. Yang, M. Hughes, U. Kammla et al., “Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis,” Journal of Immunotherapy, vol. 30, no. 8, pp. 825–830, 2007.

[44] T. J. Lynch, I. N. Bondarenko, A. Luft et al., “Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non small cell lung cancer (NSCLC),” Journal of Clinical Oncology, vol. 102, pp. 1388–1397, 2010.

[45] A. Ribas, L. H. Camacho, G. Lopez-Berestein et al., “Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206,” Journal of Clinical Oncology, vol. 23, no. 35, pp. 8968–8977, 2005.

[46] A. Ribas, V. A. Bozon, G. Lopez-Berestein et al., “Phase I trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma,” Journal of Clinical Oncology, vol. 23, no. 16S, p. 7524, 2005.

[47] A. Ribas, S. Antonia, and J. Sosman, “Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patient (pts) with advanced melanoma,” Journal of Clinical Oncology, vol. 25, p. 118s, 2007.

[48] L. H. Camacho, S. Antonia, J. Sosman et al., “Phase II/II trial of tremelimumab in patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 27, no. 7, pp. 1075–1081, 2009.

[49] J. M. Kirkwood, P. Lorigan, P. Hersey et al., “Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma,” Clinical Cancer Research, vol. 16, no. 3, pp. 1042–1048, 2010.

[50] A. Ribas, A. Hauschild, and R. Kefferd, “Phase III, open-label, randomized, comparative study of tremelimumab CP-675,206 and chemotherapy temozolomide (TMZ) or dacarbazine (DTIC) in patients with advanced melanoma,” Journal of Clinical Oncology, vol. 26, p. 486s, 2008.

[51] B. I. Rini, M. Stein, P. Shannon et al., “Phase I dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma,” Cancer, vol. 117, no. 4, pp. 758–767, 2011.

[52] K. Y. Chung, I. Gore, L. Fong et al., “Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody tremelimumab in patients with refractory metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 28, no. 21, pp. 3485–3490, 2010.

[53] C. Ralph, E. Elkord, D. J. Burt et al., “Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma,” Clinical Cancer Research, vol. 16, no. 5, pp. 1662–1672, 2010.

[54] H. Ying, L. Yang, G. Qiao et al., “Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation,” Journal of Immunology, vol. 183, no. 3, pp. 1375–1378, 2010.

[55] R. S. McHugh, M. J. Whitters, C. A. Piccirillo et al., “CD4+CD25” immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor,” Immunity, vol. 16, no. 2, pp. 311–323, 2002.

[56] M. M. Swallow, J. J. Wallin, and W. C. Sha, “B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFα,” Immunity, vol. 11, no. 4, pp. 423–432, 1999.

[57] T. R. Simpson, S. A. Quezada, and J. P. Allison, “Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS),” Current Opinion in Immunology, vol. 22, no. 3, pp. 326–332, 2010.

[58] M. A. Linterman, R. J. Rigby, R. Wong et al., “Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor genes CD28 and ICOS,” Immunity, vol. 30, no. 2, pp. 228–241, 2009.
by enhanced recruitment of effector T cells," International Immunology, vol. 17, no. 2, pp. 133–144, 2005.

[88] B. Li, M. Vanroey, C. Wang, T. H. T. Chen, A. Korman, and K. Jooss, "Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secretory tumor cell immunotherapy providing therapeutic benefit to mice with established tumors," Clinical Cancer Research, vol. 15, no. 5, pp. 1623–1634, 2009.

[89] K. Durgan, M. Ali, P. Warner, and Y. E. Latchman, "Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model," Cancer Immunology, Immunotherapy, vol. 60, no. 4, pp. 547–558, 2011.

[90] S. M. Mangsbo, L. C. Sandin, K. Anger, A. J. Korman, A. Loskog, and T. H. Töterman, "Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy," Journal of Immunotherapy, vol. 33, no. 3, pp. 225–235, 2010.

[91] T. J. Curiel, S. Wei, H. Dong et al., "Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity," Nature Medicine, vol. 9, no. 5, pp. 562–567, 2003.

[92] N. Martin-Orozco and C. Dong, "Inhibitory costimulation and anti-tumor immunity," Seminars in Cancer Biology, vol. 17, no. 4, pp. 288–298, 2007.

[93] M. Mkrtichyan, Y. G. Najjar, E. C. Raulfs et al., "Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms," European Journal of Immunology, vol. 41, no. 10, pp. 2977–2986, 2011.

[94] D. M. Benson Jr., C. E. Bakan, A. Mishra et al., "The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody," Blood, vol. 116, no. 13, pp. 2286–2294, 2010.

[95] R. Berger, R. Rotem-Yehudar, G. Slama et al., "Phase i safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies," Clinical Cancer Research, vol. 14, no. 10, pp. 3044–3051, 2008.

[96] J. Rosenblatt, B. Glotzbecker, H. Mills et al., "PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine," Journal of Immunotherapy, vol. 34, no. 5, pp. 409–418, 2011.

[97] J. R. Brahmer, S. Topalian, I. Wollner et al., "Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies," Journal of Clinical Oncology, vol. 26, p. 3006, 2008.

[98] P. A. Asciento, E. Simeone, M. Sznl, Y. X. Fu, and I. Melero, "Clinical experiences with anti-CD137 and anti-PD1 therapeutically antibodies," Seminars in Oncology, vol. 37, no. 5, pp. 508–516, 2010.

[99] K. Garber, "Beyond ipilimumab: new approaches target the immunological synapse," Journal of the National Cancer Institute, vol. 103, no. 14, pp. 1079–1082, 2011.

[100] M. L. Del Rio, C. L. Lucas, L. Buhrer, G. Rayat, and J. I. Rodriguez-Barbosa, "HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation," Journal of Leukocyte Biology, vol. 87, no. 2, pp. 223–235, 2010.

[101] G. Cai and G. J. Freeman, "The CD160, BTLA, LIGHT/ HVEM pathway: a bidirectional switch regulating T-cell activation," Immunological Reviews, vol. 229, no. 1, pp. 244–258, 2009.

[102] T. L. Murphy and K. M. Murphy, "Slow down and survive: enigmatic immunoregulation by BTLA and HVEM," Annual Review of Immunology, vol. 28, pp. 389–411, 2010.

[103] A. C. Vendel, J. Calemine-Fenaux, A. Izrael-Tomasevic, V. Chauhan, D. Arnott, and D. L. Eaton, "B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK," Journal of Immunology, vol. 182, no. 3, pp. 1509–1517, 2009.

[104] H. M’Hidi, M. L. Thibult, B. Chetaill et al., "High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia," American Journal of Clinical Pathology, vol. 132, no. 4, pp. 589–596, 2009.

[105] L. Han, W. Wang, Y. Fang et al., "Soluble B and T lymphocyte attenuator possesses antitumor effects and facilitates heat shock protein 70 vaccine-triggered antitumor immunity against a murine TC-1 cervical cancer model in vivo," Journal of Immunology, vol. 183, no. 12, pp. 7842–7850, 2009.

[106] L. Derré, J. P. Rivals, C. Jandus et al., "BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination," Journal of Clinical Investigation, vol. 120, no. 1, pp. 157–167, 2010.

[107] L. Han, W. Wang, Y. Fang et al., "Soluble B and T lymphocyte attenuator possesses antitumor effects and facilitates heat shock protein 70 vaccine-triggered antitumor immunity against a murine TC-1 cervical cancer model in vivo," Journal of Immunology, vol. 183, no. 12, pp. 7842–7850, 2009.

[108] M. Maeda, C. Carpenito, R. C. Russell et al., "Murine CD160, Ig-like receptor on NK Cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation," Journal of Immunology, vol. 175, no. 7, pp. 4426–4432, 2005.

[109] G. Cai, A. Anumantthan, J. A. Brown, E. A. Greenfield, B. Zhu, and G. J. Freeman, "CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator," Nature Immunology, vol. 9, no. 2, pp. 176–185, 2008.

[110] F. T. Liu, J. Giustini, T. Farren et al., "CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia," Blood, vol. 115, no. 15, pp. 3079–3088, 2010.

[111] T. W. Farren, J. Giustini, F.-T. Liu et al., "Differential and tumor-specific expression of CD160 in B-cell malignancies," Blood, vol. 118, no. 8, pp. 2174–2183, 2011.

[112] S. Chabot, N. Jabrane-Ferrat, K. Bigot et al., "A novel antian- giogenic and vascular normalization therapy targeted against human CD160 receptor," Journal of Experimental Medicine, vol. 208, no. 5, pp. 973–986, 2011.

[113] J. Kleeff, M. Loos, D. M. Hedderich, and H. Friess, "B7-H3 and its role in antitumor immunity," Clinical and Developmental Immunology, vol. 2010, Article ID 683875, 7 pages, 2010.

[114] W. K. Suh, B. U. Gajewksa, H. Okada et al., "The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses," Nature Immunology, vol. 4, no. 9, pp. 899–906, 2003.

[115] G. L. Sica, I. H. Choi, G. Zhu et al., "B7-H4, a molecule of the B7 family, negatively regulates T cell immunity," Immunity, vol. 18, no. 6, pp. 849–861, 2003.

[116] X. Zang, P. Loke, J. Kim, K. Murphy, R. Waitz, and J. P. Allison, "B7x: a widely expressed B7 family member that inhibits T cell activation," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10388–10392, 2003.

[117] C. He, H. Qiao, H. Jiang, and X. Sun, "The inhibitory role of b7-h4 in antitumor immunity: association with cancer
progression and survival,” *Clinical and Developmental Immunology*, vol. 2011, Article ID 695834, 8 pages, 2011.

[118] D. Quandt, E. Fiedler, D. Boettcher, W. Ch. Marsch, and B. Seliger, “B7-H4 expression in human melanoma: its association with patients’ survival and antitumor immune response,” *Clinical Cancer Research*, vol. 17, no. 10, pp. 3100–3111, 2011.

[119] I. Kryczek, L. Zou, P. Rodriguez et al., “B7-H4 expression in human melanoma: its association with patients’ survival and antitumor immune response,” *Clinical Cancer Research*, vol. 17, no. 10, pp. 3100–3111, 2011.

[120] Y. Qian, L. Shen, C. Xu et al., “Development of a novel monoclonal antibody to B7-H4: characterization and biological activity,” *European Journal of Medical Research*, vol. 16, no. 7, pp. 295–302, 2011.

[121] R. Elgueta, M. J. Benson, V. C. De Vries, A. Wasiuk, Y. Guo, and R. J. Noelle, “Molecular mechanism and function of CD40/CD40L engagement in the immune system,” *Immunological Reviews*, vol. 229, no. 1, pp. 152–172, 2009.

[122] J. Banchereau, D. Dubois, J. Fayette et al., “Functional CD40 antigen on B cells, dendritic cells and fibroblasts,” *Advances in Experimental Medicine and Biology*, vol. 378, pp. 79–83, 1995.

[123] S. A. Quezada, L. Z. Jarvinen, E. F. Lind, and R. J. Noelle, “CD40/CD154 interactions at the interface of tolerance and immunity,” *Annual Review of Immunology*, vol. 22, pp. 307–328, 2004.

[124] T. Kikuchi, S. Worgall, R. Singh, M. A. S. Moore, and R. J. Noelle, “CD40/CD40L engagement in the immune system,” *Annual Review of Immunology*, vol. 25, no. 7, pp. 871–881, 2006.

[125] Y. Qian, L. Shen, C. Xu et al., “Development of a novel monoclonal antibody to B7-H4: characterization and biological activity,” *European Journal of Medical Research*, vol. 16, no. 7, pp. 295–302, 2011.

[126] R. Elgueta, M. J. Benson, V. C. De Vries, A. Wasiuk, Y. Guo, and R. J. Noelle, “Molecular mechanism and function of CD40/CD40L engagement in the immune system,” *Immunological Reviews*, vol. 229, no. 1, pp. 152–172, 2009.

[127] J. Banchereau, D. Dubois, J. Fayette et al., “Functional CD40 antigen on B cells, dendritic cells and fibroblasts,” *Advances in Experimental Medicine and Biology*, vol. 378, pp. 79–83, 1995.

[128] S. A. Quezada, L. Z. Jarvinen, E. F. Lind, and R. J. Noelle, “CD40/CD154 interactions at the interface of tolerance and immunity,” *Annual Review of Immunology*, vol. 22, pp. 307–328, 2004.

[129] T. Kikuchi, S. Worgall, R. Singh, M. A. S. Moore, and R. J. Noelle, “Molecular mechanism and function of CD40/CD40L engagement in the immune system,” *Immunological Reviews*, vol. 229, no. 1, pp. 152–172, 2009.

[130] J. Banchereau, D. Dubois, J. Fayette et al., “Functional CD40 antigen on B cells, dendritic cells and fibroblasts,” *Advances in Experimental Medicine and Biology*, vol. 378, pp. 79–83, 1995.

[131] S. A. Quezada, L. Z. Jarvinen, E. F. Lind, and R. J. Noelle, “CD40/CD154 interactions at the interface of tolerance and immunity,” *Annual Review of Immunology*, vol. 22, pp. 307–328, 2004.

[132] T. S. Lewis, R. S. McCormick, K. Emmerton et al., “Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma,” *Clinical Cancer Research*, vol. 17, no. 14, pp. 4672–4681, 2011.

[133] Y. T. Tai, L. P. Catley, C. S. Mitsiades et al., “Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications,” *Cancer Research*, vol. 64, no. 8, pp. 2846–2852, 2004.

[134] R. Advani, A. Forero-Torres, R. R. Furman et al., “Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma,” *Journal of Clinical Oncology*, vol. 27, no. 26, pp. 4371–4377, 2009.

[135] M. Hussein, J. R. Berenson, R. Niesvizky et al., “A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma,” *Haematologica*, vol. 95, no. 5, pp. 845–848, 2010.

[136] R. R. Furman, A. Forero-Torres, A. Shustov, and J. G. Drachman, “A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia,” *Leukemia and Lymphoma*, vol. 51, no. 2, pp. 228–235, 2010.

[137] R. Lapalombella, A. Gowda, T. Joshi et al., “The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukemia,” *British Journal of Haematology*, vol. 144, no. 6, pp. 848–855, 2009.

[138] M. Luqman, S. Klabunde, K. Lin et al., “The antileukemia activity of a human anti-CD40 antagonist antibody, HCD112, on human chronic lymphocytic leukemia cells,” *Blood*, vol. 112, no. 3, pp. 711–720, 2008.

[139] D. S. Vinay and B. S. Kwon, “4-1BB signaling beyond T cells,” *Cellular and Molecular Immunology*, vol. 8, no. 4, pp. 281–284, 2011.

[140] D. S. Vinay and B. S. Kwon, “Immunotherapy targeting 4-1BB and its ligand,” *International Journal of Hematology*, vol. 83, no. 1, pp. 23–28, 2006.

[141] K. Saoulli, S. Y. Lee, J. L. Cannons et al., “CD28-independent, CD40-dependent immunity to B-cell lymphoma,” *Cancer and Lymphoma*, vol. 7, article no. 93, 2011.

[142] A. T. C. Cheuk, G. J. Mufti, and B. A. Guinn, “Role of 4-1BB during CD28 costimulation in chronic lymphocytic leukemia,” *British Journal of Haematology*, vol. 144, no. 6, pp. 848–855, 2009.

[143] M. Luqman, S. Klabunde, K. Lin et al., “The antileukemia activity of a human anti-CD40 antagonist antibody, HCD112, on human chronic lymphocytic leukemia cells,” *Blood*, vol. 112, no. 3, pp. 711–720, 2008.

[144] A. T. C. Cheuk, G. J. Mufti, and B. A. Guinn, “Role of 4-1BB in cancer immunotherapy,” *Cancer Gene Therapy*, vol. 11, no. 3, pp. 215–226, 2004.

[145] S. E. Strome, B. Martin, D. Flies et al., “Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma,” *Journal of Immunotherapy*, vol. 23, no. 4, pp. 430–437, 2000.

[146] Q. Li, A. Carr, E. Ito, S. Teitz-Tennenbaum, and A. E. Chang, “Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy,” *Cancer Research*, vol. 63, no. 10, pp. 2546–2552, 2003.

[147] I. Melero, W. W. Shuford, S. A. Newby et al., “Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors,” *Nature Medicine*, vol. 6, no. 6, pp. 682–685, 1997.
[178] X. Sun, H. Yamada, K. Shibata et al., “CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice,” *Journal of Immunology*, vol. 185, no. 4, pp. 2222–2230, 2010.

[179] J. Katz, J. E. Janik, and A. Younes, “Brentuximab vedotin (SGN-35),” *Clinical Cancer Research*, vol. 17, no. 20, pp. 6428–6436, 2011.

[180] A. Younes, N. L. Bartlett, J. P. Leonard et al., “Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas,” *New England Journal of Medicine*, vol. 363, no. 19, pp. 1812–1821, 2010.

[181] R. W. Chen, A. K. Gopal, S. E. Smith et al., “Results from a pivotal phase II study of Bretuximab vedutin (SGN-35) in patients with relapsed or refractory Hodgkin Lymphoma (HL),” *Journal of Clinical Oncology*, vol. 29, supplement 15, abstract 8031, 2011.

[182] N. L. Barlett, L. E. Grove, D. Kennedy, E. L. Sievers, and A. Forero-Torres, “Objective responses with Bretuximab vedutin (SGN-35) retreatment in CD30-positive hemalogic malignancies: a case series,” *Journal of Clinical Oncology*, vol. 28, supplement 15, abstract 8062, 2010.